Related Experiment Video
Updated: Jul 14, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
von Willebrand Factor in CHD and stroke: relationships and therapeutic implications
Marie-Therese Cooney1, Alexandra L Dudina, Patrick O'Callaghan
1Adelaide and Meath Hospital incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland.
Insights
Elevated von Willebrand factor (vWF) levels are inconsistently linked to cardiovascular disease (CVD) and stroke risk. While vWF may predict outcomes in acute conditions, current evidence doesn't support its use in routine risk assessment.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Neurology
Background:
- Atherosclerotic cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, is a leading global cause of death.
- Acute thrombotic arterial occlusion often precipitates fatal events in CVD.
- Hematologic disorders, including coagulopathies, can precipitate ischemic stroke, particularly in younger individuals.
Purpose of the Study:
- To investigate the pathophysiologic implications of elevated von Willebrand factor (vWF) levels in relation to CVD and cerebrovascular disease.
- To clarify the role of vWF in the pathogenesis of atherosclerosis, CHD, and stroke.
- To assess the utility of vWF measurement in predicting cardiovascular and cerebrovascular events.
Main Methods:
- Review of existing literature on von Willebrand factor (vWF) and its association with cardiovascular disease (CVD) and stroke.
- Analysis of studies investigating the relationship between elevated vWF levels and risk of coronary heart disease (CHD) and ischemic stroke.
- Evaluation of vWF's predictive value for outcomes in acute coronary syndromes (ACS) and stroke.
Main Results:
- Elevated vWF levels show variable and often inconsistent associations with CHD risk; causal criteria are not fully met.
- The relationship between vWF levels and stroke risk is less established.
- vWF measurement offers minimal additional predictive value for CVD risk beyond established factors like age, sex, cholesterol, and hypertension.
- vWF may be more relevant for predicting outcomes in acute coronary syndromes (ACS) and stroke.
Conclusions:
- The role of elevated von Willebrand factor (vWF) in the pathogenesis of atherosclerotic cardiovascular disease (CVD) and stroke remains poorly defined.
- Current evidence does not strongly support using vWF levels for routine CVD or stroke risk prediction.
- Further investigation is needed to determine if vWF levels can guide treatment decisions for acute coronary syndromes (ACS) or stroke.
Abstract:
Atherosclerotic cardiovascular disease (CVD), which includes coronary heart disease (CHD) and stroke, is now the most common cause of death in the middle aged and elderly in all parts of the world except subSaharan Africa. The direct cause of death is frequently an acute thrombotic arterial occlusion. Because atherosclerosis is a diffuse disease, patients with CHD also have a high risk of ischemic stroke. The hemostatic process is a needed defense mechanism to control hemorrhage after injury but at same time, if overactive, may have the potential to precipitate diseases such as myocardial infarction or stroke in the setting of atherosclerosis. In approximately 1% of all patients with ischemic stroke, and in up to 4% of young adults with stroke, the major precipitant of brain ischemia is a hematologic disorder or coagulopathy that predisposes to thrombosis. von Willebrand factor (vWF) plays an important role in platelet adhesion to subendothelial structures and in the intrinsic pathway of coagulation. It is regarded as an indirect measure of endothelial dysfunction. Deficiency of vWF in von Willebrand's disease is well established. However, much less is known regarding the pathophysiologic implications of an elevated level of vWF, particularly in relation to CVD and cerebrovascular disease. The importance of vWF in the pathogenesis of this disease is poorly defined and information is limited and inconsistent. Elevated levels of vWF have been variably linked with risk of CHD; causal criteria are not fully met. Relationships with stroke risk are even less well established. Measurement of vWF adds little to risk prediction after considering the major risk factors--age, sex, smoking, raised blood cholesterol, and hypertension. vWF may have a greater role in predicting outcome in subjects with acute coronary syndromes (ACS), stroke, and perhaps atrial fibrillation. Investigation of the use of vWF level to guide treatment of ACS or stroke is ongoing; however, there is no compelling evidence to date.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemorrhagic Stroke ll: Pathophysiology
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis

